A randomised phase III double-blind placebo-controlled study of Regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - INTEGRATE II

  • Strickland, Andrew (Primary Chief Investigator (PCI))
  • Lau, David (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Ref number: HREC/15/HAWKE/491
SSA Ref number: SSA/16/MonH/287
Monash Health HREC Ref: RES-16-0000449X
SEO Code: 920102 Cancer and Related Disorders
StatusActive
Effective start/end date8/09/16 → 21/03/26